Pharmaceutical Executive: June 2023

With the sales boom from COVID-19 products now in the rear-view, a resetting is underway for those in Pharm Exec’s listing of the top biopharma producers—shifting attention to new Rx roads ahead and the steady strategies needed to navigate a bumpy business terrain.

Jag Dosanjh, president of US neuroscience and eye care for AbbVie and HBA’s 2023 honorable mentor of the year, shares what leadership qualities are most important in today’s “people industry”—and the impact more voices can make in stakeholder communication and messaging.

The core building blocks of trust must be operationalized for pharma companies to strengthen their social contract, deliver business value, and improve patients’ quality of life.

The new era of generative AI is poised to impact pharma marketing and engagement in powerful and lasting ways. But amid all the technological praise, what are the key considerations brand teams must navigate?

Amid the shifting focus from primary care to specialty care, using data-driven tactics can create tailored campaigns and meaningful relationships with nurse practitioners and physician assistants.

The Medicare Part D cap won’t solve need for financial assistance.

The impact on clinical trial staffing would be particularly significant.

Such a scenario is one possibility as the bear market languishes on.

Creative audacity and innovation often take a backseat to rigid regulatory adherence in pharma advertising—but there are exceptions.

Advancing the concept of "health competencies" remains elusive.

This month, we deliver deep dives into the industry's commercial output and outlook and how drugmakers are faring in their public trust mandate—two areas where respective growth pursuits can often go hand-in-hand.

As conference season ramps up, it's a good time to reflect on the impact advances in pharma have on patients.

Click the title above for a link to open the Pharmaceutical Executive June 2023 issue in an interactive PDF format.

Agency seeks added resources and new approaches to accelerate more of these promising treatments to the market.